ADVANZ PHARMA partners with Ashfield Engage to deliver talent acquisition strategy

ADVANZ PHARMA is a global specialty pharmaceutical company focused on complex medicines in Europe. In June 2021, Nordic Capital acquired ADVANZ PHARMA, resulting in significant investment which will help fuel the company’s strategic growth and allow it to invest in future pipeline and M&A activities.

The partnership will see Ashfield Engage craft large-scale talent acquisition initiatives in Germany, France, Spain, Italy, Denmark, UK, and the Nordics. This will support ADVANZ PHARMA as it works to sustain its rapid growth and maximize on the increasing market opportunities for critical specialty medicines in these key markets helping further broaden access and choice to these medicines for both prescribers and patients.

The results of the initiative will see Ashfield Engage recruiting over 60 specialists directly to ADVANZ PHARMA’s headcount. Roles will include positions across key account management, brand marketing, market access, medical science liaison, health economics and outcomes research (HEOR), sales force effectiveness (SFE), and customer service, along with regional European and above country roles.

Ashfield Engage will take a consultative approach and build bespoke strategic talent structures for each country to ensure elite talent is onboarded.

Eoin McAtamney, Vice President, International Business Development at Ashfield Engage, commented: “We are delighted to be partnering with such a dynamic and fast-growing organization as ADVANZ PHARMA, who have the patient at the core of what they do. They are experiencing incredible growth and have many exciting opportunities ahead driven by a rich pipeline, that can only be accelerated through recruiting the right talent resource.

“We’re thrilled to be playing a part in that acceleration by leveraging our local expertise country to country across Europe, and our stellar track record in building first-class teams thus delivering real value to our clients. We have the capabilities to deliver a best-in-market experience for not only our clients but also the people we will work with as part of this European talent acquisition initiative and are excited to be involved in the next chapter of ADVANZ PHARMA’s story.”

Paul Burden, Chief Commercial Officer, Strategic Growth Unit at ADVANZ PHARMA added: “We are really pleased to be collaborating with Ashfield Engage at such a pivotal time for our business. Our pipeline and forecasted growth mean we need to act swiftly and acquire the best talent across Europe to ensure our critical medicines can reach the patients that need them most.

“Ashfield Engage has the local expertise to support with clearly defining role requirements to ensure we identify and hire the best people. They understand the nuances of each European country enabling them to build a tailored strategy that will be successful in each market. We’re confident together we can work to place ADVANZ PHARMA in a truly competitive position moving forward.”